Literature DB >> 12649774

Methadone maintenance treatment and St. John's Wort - a case report.

D Eich-Höchli, R Oppliger, K Powell Golay, P Baumann, C B Eap.   

Abstract

St. John's wort, a popular over-the-counter drug for treatment of depression, might reduce concentrations of drugs such as cyclosporin and indinavir and lead to drug resistance and treatment failure. No studies as yet have examined its influence on methadone plasma levels. The trough methadone plasma levels were measured in four patients (2 males, median age: 31 years; range 19 - 40 years) in methadone maintenance treatment just before the introduction of St. John's wort (900 mg/d) and after a median period of 31-day treatment (range 14 - 47). The study was proposed to addict patients about to start an antidepressant therapy. Introduction of St. John's wort resulted in a strong reduction of (R,S)-methadone concentration-to-dose ratios in the four median patients included, with a median decrease to 47 % of the original concentration (range: 19 % - 60 % of the original concentration). Two patients reported symptoms that suggested a withdrawal syndrome. Thus, prescription of St. John's wort might decrease methadone blood levels and induce withdrawal symptoms which, if not correctly identified and handled (by changing the antidepressant or by increasing the methadone dose), might cause unnecessary discomfort to the patient, lead to resumption of illicit drug uses, or be a risk factor for discontinuation of the methadone or antidepressant treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649774     DOI: 10.1055/s-2003-38090

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  11 in total

Review 1.  The impact of substance abuse on the care of African Americans and Latinos with HIV/AIDS.

Authors:  Anita C Vaughn
Journal:  J Natl Med Assoc       Date:  2004-02       Impact factor: 1.798

Review 2.  Drug interactions with herbal medicines.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

Review 3.  Transporter-Mediated Disposition of Opioids: Implications for Clinical Drug Interactions.

Authors:  Robert Gharavi; William Hedrich; Hongbing Wang; Hazem E Hassan
Journal:  Pharm Res       Date:  2015-05-14       Impact factor: 4.200

4.  St. John's wort does not interfere with therapeutic drug monitoring of 12 commonly monitored drugs using immunoassays.

Authors:  Amitava Dasgupta; Gertie Tso; Kathy Szelei-Stevens
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

Review 5.  Drug interactions with St John's wort : mechanisms and clinical implications.

Authors:  Marcus Mannel
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 6.  Interactions between herbal medicines and prescribed drugs: an updated systematic review.

Authors:  Angelo A Izzo; Edzard Ernst
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 7.  Interindividual variability of methadone response: impact of genetic polymorphism.

Authors:  Yongfang Li; Jean-Pierre Kantelip; Pauline Gerritsen-van Schieveen; Siamak Davani
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

8.  Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

Authors:  Mohammad-Reza Shiran; Martin S Lennard; Mohammad-Zafar Iqbal; Oldwale Lagundoye; Nicholas Seivewright; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

Review 9.  Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations.

Authors:  Francesca Borrelli; Angelo A Izzo
Journal:  AAPS J       Date:  2009-10-27       Impact factor: 4.009

Review 10.  Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).

Authors:  Sompon Wanwimolruk; Virapong Prachayasittikul
Journal:  EXCLI J       Date:  2014-04-02       Impact factor: 4.068

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.